SNDX FY 2025 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$172M+627.8% YoY

Gross Profit

$165M96.0% margin

Operating Income

-$273M-158.4% margin

Net Income

-$285M-165.6% margin

EPS (Diluted)

$-3.30

Cash Flow

Operating Cash Flow

-$323M

Free Cash Flow

-$323M

Stock-Based Comp.

$48M

Balance Sheet

Total Assets

$530M

Total Liabilities

$465M

Stockholders' Equity

$65M

Cash & Equivalents

$135M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$172M	$24M	+627.8%
Gross Profit	$165M	$23M	+623.6%
Operating Income	-$273M	-$340M	+19.6%
Net Income	-$285M	-$319M	+10.5%